CellWell record HH-543307
Efficacy and safety of sulforaphane in schizophrenia: a systematic review and meta-analysis of randomized controlled trials
Kassar O; M Mansour ME; Farag N; Selim A; Kewiaa Y; Yousef O; Hassan O
BMC psychiatry ยท 2025
In plain language
A meta-analysis of four randomized trials (369 schizophrenia patients) found sulforaphane modestly improved negative symptoms at 12 weeks and general psychopathology, with no cognitive benefit and no significant change in PANSS total scores.
- Evidence
- Established
- Design
- Meta-analysis
Cite this record: https://thecellwell.org/studies/HH-543307
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.